ARB Corporation (ASX:ARB) Eyes U.S. Growth as Export Sales Surge 15% in 1HFY25

ARB Corporation Limited (ASX:ARB) is an ASX-listed company that specialises in designing and manufacturing premium motor vehicle accessories. In the first half of the financial year 2025 (1HFY25), the company recorded a 15.4% YoY growth in export sales, primarily driven by the U.S. market. …

Team Kalkine | 24 Feb 2025| Read Time : 10 Mins

Ai-Media Technologies (ASX:AIM) Gains Momentum in FY24, Shares Jump 178% in a Year

Ai-Media Technologies Limited (ASX:AIM), an international provider of AI-powered captioning, transcription, and translation services, delivered encouraging financial results in the financial year 2024 (FY24) on the back of the rising adoption of its AI-driven solutions. The company achieved higher technology revenue, improved gross margins, …

Team Kalkine | 19 Feb 2025| Read Time : 10 Mins

Westgold Resources (ASX:WGX) Sees Higher Gold Production in 1HFY25 but Lowers Full-Year Guidance

Western Australia-based gold development, exploration and mining company Westgold Resources (ASX: WGX) saw a significant year-on-year revenue increase of 71.84% in the first half of the financial year 2025 (1HFY25). Revenue reached AUD 623.95 million, compared to AUD 363.09 million for the same period …

Team Kalkine | 18 Feb 2025| Read Time : 10 Mins

Alliance Aviation Services (ASX:AQZ) Plans Fleet Expansion, Tech Investments & Cost Efficiency in FY25

Alliance Aviation Services Limited (ASX:AQZ) is an ASX-listed company that offers contract, charter, and allied aviation and maintenance services. With a growing fleet and strategic expansion, AQZ intends to strengthen its position in the aviation industry. Positive Market Indicators According to the latest Australian …

Team Kalkine | 17 Feb 2025| Read Time : 10 Mins

Neuren Pharmaceuticals (ASX:NEU) Records 594% Jump in 1HFY24 Royalty Revenue, Expects Continued Growth in FY24

Neuren Pharmaceuticals Limited (ASX:NEU), an ASX-listed biopharmaceutical company focused on neurological disorder treatments, has reported significant financial and regulatory developments. Recently, the company has experienced substantial growth in royalty revenue, strengthened its partnership with Acadia Pharmaceuticals, and is advancing clinical trials for NNZ-2591. Recent …

Team Kalkine | 12 Feb 2025| Read Time : 10 Mins

FireFly Metals (ASX:FFM) Soars 112% in a Year On Resource Growth and Key Developments

An emerging copper-gold company, FireFly Metals Ltd (ASX:FFM) has seen its share price surge by over 112% in the past year, driven by significant resource expansion and encouraging drilling results at its Green Bay copper-gold project in Newfoundland, Canada. Major Resource Upgrade Sparks Rally …

Team Kalkine | 11 Feb 2025| Read Time : 10 Mins

CSL (ASX:CSL) Eyes Double-Digit Earnings Growth in FY25: What’s Driving the Momentum?

CSL Limited (ASX:CSL) is an ASX-listed global biopharmaceutical company. The company achieved an 11% YoY jump in its total revenue in the fiscal year ended 30 June 2024 (FY24), reaching USD 14.8 billion. Net Profit After Tax (NPAT) during the year surged by 20% …

Team Kalkine | 10 Feb 2025| Read Time : 10 Mins

News